Serveur d'exploration sur l'opéra

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.

Identifieur interne : 000633 ( Ncbi/Merge ); précédent : 000632; suivant : 000634

Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.

Auteurs : M G Minervini [Italie] ; P. Priore ; A. Farolfi ; B. Cesana ; P L Morselli

Source :

RBID : pubmed:1971117

English descriptors

Abstract

In this double-blind study, alpidem, a new imidazo-pyridine anxiolytic drug, was compared with placebo in order to test its efficacy and safety in chronic schizophrenic in-patients suffering from anxiety not directly related to the schizophrenic process. Sixty-six patients aged from 18 to 65 entered the trial. They also scored at least 18 on the Hamilton Rating Scale for Anxiety (HRSA) after a seven-day placebo run-in. Improvement in symptoms was evaluated by means of the HRSA, the Brief Psychiatric Rating Scale (BPRS), a Visual Analogue Scale (VAS), and the Clinical Global Impression score (CGI). Thirty-three patients were randomly allocated to alpidem and 33 to placebo. Alpidem was significantly more effective (P less than 0.0001) than placebo in improving HRSA scores (total score and factorial scores for somatic and psychic anxiety), BPRS, and VAS. Considering the results of CGI at 21 day, more patients were moderately to markedly improved on alpidem (30/33) than on placebo (2/33) (P less than 0.0001). The efficacy index, according to CGI, was significantly better (P less than 0.001 at least) for alpidem than for placebo. Side-effects were negligible in both groups.

DOI: 10.1055/s-2007-1014491
PubMed: 1971117

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:1971117

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.</title>
<author>
<name sortKey="Minervini, M G" sort="Minervini, M G" uniqKey="Minervini M" first="M G" last="Minervini">M G Minervini</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Psychiatry Opera Don Uva Hospital, Bisceglie, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Psychiatry Opera Don Uva Hospital, Bisceglie</wicri:regionArea>
<wicri:noRegion>Bisceglie</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Priore, P" sort="Priore, P" uniqKey="Priore P" first="P" last="Priore">P. Priore</name>
</author>
<author>
<name sortKey="Farolfi, A" sort="Farolfi, A" uniqKey="Farolfi A" first="A" last="Farolfi">A. Farolfi</name>
</author>
<author>
<name sortKey="Cesana, B" sort="Cesana, B" uniqKey="Cesana B" first="B" last="Cesana">B. Cesana</name>
</author>
<author>
<name sortKey="Morselli, P L" sort="Morselli, P L" uniqKey="Morselli P" first="P L" last="Morselli">P L Morselli</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:1971117</idno>
<idno type="pmid">1971117</idno>
<idno type="doi">10.1055/s-2007-1014491</idno>
<idno type="wicri:Area/PubMed/Corpus">000777</idno>
<idno type="wicri:Area/PubMed/Curation">000777</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000730</idno>
<idno type="wicri:Area/Ncbi/Merge">000633</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.</title>
<author>
<name sortKey="Minervini, M G" sort="Minervini, M G" uniqKey="Minervini M" first="M G" last="Minervini">M G Minervini</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Psychiatry Opera Don Uva Hospital, Bisceglie, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Psychiatry Opera Don Uva Hospital, Bisceglie</wicri:regionArea>
<wicri:noRegion>Bisceglie</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Priore, P" sort="Priore, P" uniqKey="Priore P" first="P" last="Priore">P. Priore</name>
</author>
<author>
<name sortKey="Farolfi, A" sort="Farolfi, A" uniqKey="Farolfi A" first="A" last="Farolfi">A. Farolfi</name>
</author>
<author>
<name sortKey="Cesana, B" sort="Cesana, B" uniqKey="Cesana B" first="B" last="Cesana">B. Cesana</name>
</author>
<author>
<name sortKey="Morselli, P L" sort="Morselli, P L" uniqKey="Morselli P" first="P L" last="Morselli">P L Morselli</name>
</author>
</analytic>
<series>
<title level="j">Pharmacopsychiatry</title>
<idno type="ISSN">0176-3679</idno>
<imprint>
<date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Anti-Anxiety Agents (adverse effects)</term>
<term>Anti-Anxiety Agents (therapeutic use)</term>
<term>Anxiety (drug therapy)</term>
<term>Anxiety (etiology)</term>
<term>Anxiety (psychology)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Imidazoles (adverse effects)</term>
<term>Imidazoles (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Psychiatric Status Rating Scales</term>
<term>Pyridines (adverse effects)</term>
<term>Pyridines (therapeutic use)</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Schizophrenia (complications)</term>
<term>Schizophrenic Psychology</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Anti-Anxiety Agents</term>
<term>Imidazoles</term>
<term>Pyridines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Anti-Anxiety Agents</term>
<term>Imidazoles</term>
<term>Pyridines</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Schizophrenia</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Anxiety</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Anxiety</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en">
<term>Anxiety</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Psychiatric Status Rating Scales</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Schizophrenic Psychology</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">In this double-blind study, alpidem, a new imidazo-pyridine anxiolytic drug, was compared with placebo in order to test its efficacy and safety in chronic schizophrenic in-patients suffering from anxiety not directly related to the schizophrenic process. Sixty-six patients aged from 18 to 65 entered the trial. They also scored at least 18 on the Hamilton Rating Scale for Anxiety (HRSA) after a seven-day placebo run-in. Improvement in symptoms was evaluated by means of the HRSA, the Brief Psychiatric Rating Scale (BPRS), a Visual Analogue Scale (VAS), and the Clinical Global Impression score (CGI). Thirty-three patients were randomly allocated to alpidem and 33 to placebo. Alpidem was significantly more effective (P less than 0.0001) than placebo in improving HRSA scores (total score and factorial scores for somatic and psychic anxiety), BPRS, and VAS. Considering the results of CGI at 21 day, more patients were moderately to markedly improved on alpidem (30/33) than on placebo (2/33) (P less than 0.0001). The efficacy index, according to CGI, was significantly better (P less than 0.001 at least) for alpidem than for placebo. Side-effects were negligible in both groups.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">1971117</PMID>
<DateCreated>
<Year>1990</Year>
<Month>06</Month>
<Day>20</Day>
</DateCreated>
<DateCompleted>
<Year>1990</Year>
<Month>06</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised>
<Year>2012</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0176-3679</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>23</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1990</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Pharmacopsychiatry</Title>
<ISOAbbreviation>Pharmacopsychiatry</ISOAbbreviation>
</Journal>
<ArticleTitle>Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.</ArticleTitle>
<Pagination>
<MedlinePgn>102-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>In this double-blind study, alpidem, a new imidazo-pyridine anxiolytic drug, was compared with placebo in order to test its efficacy and safety in chronic schizophrenic in-patients suffering from anxiety not directly related to the schizophrenic process. Sixty-six patients aged from 18 to 65 entered the trial. They also scored at least 18 on the Hamilton Rating Scale for Anxiety (HRSA) after a seven-day placebo run-in. Improvement in symptoms was evaluated by means of the HRSA, the Brief Psychiatric Rating Scale (BPRS), a Visual Analogue Scale (VAS), and the Clinical Global Impression score (CGI). Thirty-three patients were randomly allocated to alpidem and 33 to placebo. Alpidem was significantly more effective (P less than 0.0001) than placebo in improving HRSA scores (total score and factorial scores for somatic and psychic anxiety), BPRS, and VAS. Considering the results of CGI at 21 day, more patients were moderately to markedly improved on alpidem (30/33) than on placebo (2/33) (P less than 0.0001). The efficacy index, according to CGI, was significantly better (P less than 0.001 at least) for alpidem than for placebo. Side-effects were negligible in both groups.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Minervini</LastName>
<ForeName>M G</ForeName>
<Initials>MG</Initials>
<AffiliationInfo>
<Affiliation>Department of Psychiatry Opera Don Uva Hospital, Bisceglie, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Priore</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Farolfi</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cesana</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morselli</LastName>
<ForeName>P L</ForeName>
<Initials>PL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>GERMANY, WEST</Country>
<MedlineTA>Pharmacopsychiatry</MedlineTA>
<NlmUniqueID>8402938</NlmUniqueID>
<ISSNLinking>0176-3679</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>I93SC245QZ</RegistryNumber>
<NameOfSubstance UI="C052036">alpidem</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014151">Anti-Anxiety Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001007">Anxiety</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016032">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012565">Schizophrenic Psychology</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>1990</Year>
<Month>3</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>1990</Year>
<Month>3</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>1990</Year>
<Month>3</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">1971117</ArticleId>
<ArticleId IdType="doi">10.1055/s-2007-1014491</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Italie</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Cesana, B" sort="Cesana, B" uniqKey="Cesana B" first="B" last="Cesana">B. Cesana</name>
<name sortKey="Farolfi, A" sort="Farolfi, A" uniqKey="Farolfi A" first="A" last="Farolfi">A. Farolfi</name>
<name sortKey="Morselli, P L" sort="Morselli, P L" uniqKey="Morselli P" first="P L" last="Morselli">P L Morselli</name>
<name sortKey="Priore, P" sort="Priore, P" uniqKey="Priore P" first="P" last="Priore">P. Priore</name>
</noCountry>
<country name="Italie">
<noRegion>
<name sortKey="Minervini, M G" sort="Minervini, M G" uniqKey="Minervini M" first="M G" last="Minervini">M G Minervini</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000633 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000633 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:1971117
   |texte=   Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:1971117" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a OperaV1 

Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Oct 8 06:48:41 2020